Slide 1: Reaching Patients Through Immunology Innovation
Reaching Patients Through Immunology Innovation 3 Q 2 0 2 5 F I N AN C I AL R E S U LT S C AL L O C T O B E R 3 0 , 2 0 2 5 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: 2025 Strategic Priorities
2025 Strategic Priorities Reach more patients Expand next wave with VYVGART Fuel pipeline growth of innovation 10 Phase 3s 4 New PFS Launch Molecules in 10 Phase 2s Phase 1 33
Slide 4: Ongoing Commitment to Innovation in Rare Neuromuscular Disease
Ongoing Commitment to Innovation in Rare Neuromuscular Disease Positive Seronegative gMG Data Robust Evidence Generation Sustained MSE Study met primary gMG endpoint Significant steroid reduction at 6 months, sustained through 18 months (p-value=0.0068) No new safety ADHERE+: Sustained Functional Im
Slide 5: Advancing a Late-Stage Pipeline with Transformative Potential
Advancing a Late-Stage Pipeline with Transformative Potential Efgartigimod Empasiprubart ARGX-119 First and only Potent C2 sweeping MuSK agonist Fc Fragment antibody antibody indications indications indications Ongoing Ongoing Registrational registrational registrational study to start studies studi
Slide 6: Five Registrational Readouts in 2026
Five Registrational Readouts in 2026 Ocular MG MMN TED IMM ITP Primary Endpoint: Primary Endpoint: Primary Endpoint: Primary Endpoint: Primary Endpoint: MGII PRO ocular score Grip strength Proptosis responders Mean Total Improvement Cumulative disease Score (TIS) control Opportunity to Address Signi
Slide 7: Driving Long-Term Sustainable Growth through Innovation
Driving Long-Term Sustainable Growth through Innovation Continuous Innovation Investing in Our Future Scaling U.S. Manufacturing to support future VYVGART and pipeline growth Collaborators 4 New Molecules in Phase 1 by year end 20 Active IIP Programs 7
Slide 8: Product Net Sales for Q3 of $1.13 billion
Product Net Sales for Q3 of $1.13 billion Product Net Sales by Quarter Q3 2025: growth of 96% vs Q3 2024 19% (in millions of $) Q3 2025 Q3 2024 Growth Growth % * 1,127 $’m US 964 492 471 96% 949 Japan 60 24 36 148% 790 737 RoW 94 46 49 107% China supply 9 11 (2) (17%) 573 478 Total 1,127 573 554 96%
Slide 9: Q3 2025 Financial Summary
Q3 2025 Financial Summary Three months ended Nine months ended September 30 September 30 (in million of $) 2025 2024 2025 2024 Product net sales 1,127 573 2,866 1,449 Other operating income 24 16 60 42 Total operating income 1,151 589 2,926 1,491 Cost of sales (109) (59) (301) (155) Research and dev
Slide 10: Delivering Transformative Impact for Patients
Delivering Transformative Impact for Patients Amanda, Patient 10
Slide 11: Maximizing the VYVGART Opportunity
Maximizing the VYVGART Opportunity COMMERCIAL GROWTH DRIVERS 97 % YoY revenue growth Presentation 260 First-time VYVGART prescribers since PFS launch 3Q growth across all Geography indications, all regions 11
Slide 12: Growing VYVGART Leadership in MG
Growing VYVGART Leadership in MG Path to 60K Addressable Patients 2025 Progress U.S. Addressable MG Patients +25K +7K Seronegative sBLA Submission Planned by end of 2025 +11K Growth in Biologics 60K Share of Market Ocular 17K Pre-Filled Syringe Seronegative Launched In all major markets Addressable
Slide 13: Delivering Impact for CIDP Patients
Delivering Impact for CIDP Patients I missed the simple activities… walking my children to the school bus… VYVGART Hytrulo is not just a medicine, it’s freedom. I’m planning a 10-day cruise, and I do not need to worry about being home for an injection – Sasha, CIDP Patient 13
Slide 14: Innovation has no meaning unless it provides real benefit to patients
Innovation has no meaning unless it provides real benefit to patients 14
Slide 15: Alternative Performance Measures Statement
Alternative Performance Measures Statement In this document, argenx's financial results are provided in accordance with IFRS® Accounting Standards (IFRS) and using a non-IFRS financial measure, cash, cash equivalents and current financial assets. This value should not be viewed as a substitute for t